Characteristics of Chemotherapy Side Effects in Patients with Nasopharyngeal Cancer
DOI:
https://doi.org/10.51601/ijhp.v5i1.400Abstract
This study investigates the characteristics of post-chemotherapy side effects in patients with nasopharyngeal cancer at Dr. Wahidin Sudirohusodo Hospital in Makassar during 2023. Utilizing secondary data, the research analyzes the prevalence of side effects based on gender and age. The findings reveal that male patients predominantly experience gastrointestinal (11.6%) and respiratory (16.8%) side effects, while female patients report higher rates of neuropathy (22.2%). In terms of age, adults exhibit the highest prevalence of gastrointestinal effects (12.1%) and combined effects (5.3%), whereas adolescents show significant rates of neuropathy (40.0%) and respiratory complications (60.0%). Elderly patients experience similar gastrointestinal and neuropathic toxicities (17.3% each), but at lower frequencies. Notably, no cases of nasopharyngeal cancer were reported in toddlers and children, indicating that this malignancy primarily affects older age groups. The study underscores the need for increased public awareness regarding nasopharyngeal cancer, particularly among vulnerable demographics, to promote early detection and prevention. Additionally, enhancing public knowledge about nasopharyngeal cancer and its risk factors is crucial for better understanding and management of the disease. Future research should focus on elaborating the specific side effects associated with each affected system to provide comprehensive insights into the impact of chemotherapy on nasopharyngeal cancer patients. Overall, this study contributes valuable information to the understanding of chemotherapy-related side effects in nasopharyngeal cancer, emphasizing the importance of tailored management strategies to improve patient outcomes and quality of life.
References
A. W. M. Lee et al., “NPC‐0501 Trial on The Value of Changing Chemoradiotherapy Sequence, Replacing 5‐Fluorouracil With Capecitabine, and Altering Fractionation for Patients with Advanced Nasopharyngeal Carcinoma,” Cancer, vol. 126, no. 16, pp. 3674–3688, Aug. 2020, doi: 10.1002/cncr.32972.
L. S. Alhumaidan et al., “Incidence, Pattern, and Possible Risk Factors for Nasopharyngeal Cancer in the Qassim Region,” Cureus, vol. 15, no. 11, pp. 1–7, Nov. 2023, doi: 10.7759/cureus.49355.
A. Rachman, H. Shatri, and R. Salamat, “Correlation Between Higher Cumulative Dose of Cisplatin for Concurrent Chemoradiation and Acute Kidney Disease Incidence Among Nasopharyngeal Carcinoma Patients: A Comparative Study,” Int. J. Gen. Med., vol. 14, pp. 10527–10539, Dec. 2021, doi: 10.2147/IJGM.S343644.
L. Mustajabah, D. Setiawan, and Sudarso, “Pola Terapi Pada Pasien Kanker Nasofaring di RSUD Prof. Dr. Margono Soekarjo,” PHARMACY, vol. 9, no. 2, pp. 94–117, 2012.
X. Li, D. Xu, S. Lou, and J. Li, “Application and Effect Evaluation of Case Management Nursing Practice Mode in Patients with Precision Radiotherapy For Nasopharyngeal Carcinoma,” Precis. Med. Sci., vol. 12, no. 2, pp. 76–82, Jun. 2023, doi: 10.1002/prm2.12096.
P.-Y. OuYang et al., “A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma,” Oncologist, vol. 24, no. 4, pp. 505–512, Apr. 2019, doi: 10.1634/theoncologist.2018-0522.
X. Ji et al., “Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer,” Front. Oncol., vol. 11, pp. 1–9, May 2021, doi: 10.3389/fonc.2021.659987.
Y. Xu, T. Huang, M. Mao, J. Zhai, and J. Chen, “Metastatic Patterns and Prognosis of De Novo Metastatic Nasopharyngeal Carcinoma in The United States,” Laryngoscope, vol. 131, no. 4, pp. 1–9, Apr. 2021, doi: 10.1002/lary.28983.
S.-S. Yang et al., “Effect of Induction Chemotherapy in Nasopharyngeal Carcinoma: An Updated Meta-Analysis,” Front. Oncol., vol. 10, pp. 1–9, Jan. 2021, doi: 10.3389/fonc.2020.591205.
X.-S. Sun et al., “Optimizing the Treatment Pattern for De Novo Metastatic Nasopharyngeal Carcinoma Patients: A Large-Scale Retrospective Cohort Study,” Front. Oncol., vol. 10, pp. 1–9, Oct. 2020, doi: 10.3389/fonc.2020.543646.
D. Jiang, J. Cao, L. Guo, Y. Chen, G. Yuan, and J. Huang, “Induction Chemotherapy with Sequential Nimotuzumab Plus Concurrent Chemoradiotherapy in Advanced Nasopharyngeal Carcinoma: A Retrospective Real-World Study,” Medicine (Baltimore)., vol. 102, no. 4, pp. 1–6, Jan. 2023, doi: 10.1097/MD.0000000000032732.
H. B. Low et al., “DUSP16 Promotes Cancer Chemoresistance Through Regulation of Mitochondria-Mediated Cell Death,” Nat. Commun., vol. 12, no. 1, p. 2284, Apr. 2021, doi: 10.1038/s41467-021-22638-7.
A. Vemula and S. P. Dhanasekaran, “Uncommon Presentations of Nasopharyngeal Carcinoma: A Report of Two Cases,” Cureus, vol. 16, no. 9, pp. 1–9, Sep. 2024, doi: 10.7759/cureus.69643.
S. Sinha, R. Winters, and A. Gajra, Nasopharyngeal Cancer. StatPearls [Internet]: StatPearls Publishing, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK459256/
J. Dai et al., “Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma,” JAMA Oncol., vol. 10, no. 4, p. 456, Apr. 2024, doi: 10.1001/jamaoncol.2023.6552.
S. A. Gondhowiardjo et al., “Immune Cells Markers within Local Tumor Microenvironment are Associated with EBV Oncoprotein in Nasopharyngeal Cancer,” BMC Cancer, vol. 22, no. 1, p. 887, Aug. 2022, doi: 10.1186/s12885-022-09948-9.
H. Zhou et al., “Effects of Oral Maintenance Chemotherapy and Predictive Value of Circulating EBV DNA in Metastatic Nasopharyngeal Carcinoma,” Cancer Med., vol. 9, no. 8, pp. 2732–2741, Apr. 2020, doi: 10.1002/cam4.2926.
A. Reffai et al., “Epidemiological Profile and Clinicopathological, Therapeutic, and Prognostic Characteristics of Nasopharyngeal Carcinoma in Northern Morocco,” Cancer Control, vol. 28, pp. 1–12, Jan. 2021, doi: 10.1177/10732748211050587.
K. Fatima et al., “Induction versus Adjuvant Chemotherapy Combined with Concurrent Chemoradiation: What Is Beneficial in Locally Advanced Nasopharyngeal Carcinoma—A 5-Year Comparative Study at a Tertiary Care Center in North India,” South Asian J. Cancer, vol. 14, no. 16, pp. 6727–6739, Jun. 2024.
Sugiyono, Metode Penelitian Kuantitatif, Kualitatif R&D. Bandung: Alfabeta, 2019.
I. K. Swarjana, Metode Penelitian Kesehatan. Surabaya: Andi Offset, 2016.
Y. Agnesia, S. W. Sari, H. Nu’man, D. W. Ramadhani, and Nopianto, Buku Ajar Metode Penelitian Kesehatan. Pekalongan: Penerbit NEM, 2023.
W. Liao et al., “Concurrent Chemoradiotherapy with Nedaplatin Versus Cisplatin in Stage II–IVB Nasopharyngeal Carcinoma: An Open-Label, Non-Inferiority, Randomised Phase 3 Trial,” Lancet Oncol., vol. 19, no. 4, pp. 461–473, Apr. 2018, doi: 10.1016/S1470-2045(18)30104-9.
W. Fang et al., “Camrelizumab (SHR-1210) Alone or in Combination with Gemcitabine Plus Cisplatin For Nasopharyngeal Carcinoma: Results From Two Single-Arm, Phase 1 Trials,” Lancet Oncol., vol. 19, no. 10, pp. 1338–1350, Oct. 2018, doi: 10.1016/S1470-2045(18)30495-9.
L. Kong, Y. Zhang, C. Hu, Y. Guo, and J. J. Lu, “Effects of Induction Taxotere, Platinum, and Fluorouracil (TPF) Chemotherapy in Patients with Stage III And IVA/B Nasopharyngeal Cancer Treated with Concurrent Chemoradiation Therapy: Final Results of Two Parallel Phase 2 Clinical Trials,” Lancet, vol. 388, p. S46, Oct. 2016, doi: 10.1016/S0140-6736(16)31973-0.
X. Lv et al., “Induction Chemotherapy with Lobaplatin and Fluorouracil Versus Cisplatin and Fluorouracil Followed by Chemoradiotherapy in Patients with Stage III–IVB Nasopharyngeal Carcinoma: An Open-Label, Non-Inferiority, Randomised, Controlled, Phase 3 Trial,” Lancet Oncol., vol. 22, no. 5, pp. 716–726, May 2021, doi: 10.1016/S1470-2045(21)00075-9.
Y.-P. Chen et al., “Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Multicentre, Open-Label, Parallel-Group, Randomised, Controlled, Phase 3 Trial,” Lancet, vol. 398, no. 10297, pp. 303–313, Jul. 2021, doi: 10.1016/S0140-6736(21)01123-5.
T.-M. Chen, K.-C. Lin, K. S.-P. Yuan, C.-L. Chang, J.-M. Chow, and S.-Y. Wu, “Treatment of Advanced Nasopharyngeal Cancer Using Low or High-Dose Concurrent Chemoradiotherapy with Intensity-Modulated Radiotherapy: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study,” Radiother. Oncol., vol. 129, no. 1, pp. 23–29, Oct. 2018, doi: 10.1016/j.radonc.2017.12.004.
G. H. Lyman and A. Sparreboom, “Chemotherapy Dosing in Overweight and Obese Patients with Cancer,” Nat. Rev. Clin. Oncol., vol. 10, no. 8, pp. 451–459, Aug. 2013, doi: 10.1038/nrclinonc.2013.108.
A. M. Moyer, E. T. Matey, and V. M. Miller, “Individualized Medicine: Sex, Hormones, Genetics, and Adverse Drug Reactions,” Pharmacol. Res. Perspect., vol. 7, no. 6, pp. 1–9, Dec. 2019, doi: 10.1002/prp2.541.
B. Zhang et al., “Association of Chemoradiotherapy Regimens and Survival Among Patients With Nasopharyngeal Carcinoma,” JAMA Netw. Open, vol. 2, no. 10, pp. 1–20, Oct. 2019, doi: 10.1001/jamanetworkopen.2019.13619.
E. J. Bartley and R. B. Fillingim, “Sex Differences in Pain: A Brief Review of Clinical and Experimental Findings,” Br. J. Anaesth., vol. 111, no. 1, pp. 52–58, Jul. 2013, doi: 10.1093/bja/aet127.
M. Jesus, A. Cabral, C. Monteiro, A. P. Duarte, and M. Morgado, “Peripheral Neuropathy Potentially Associated to Poly (ADP-Ribose) Polymerase Inhibitors: An Analysis of the Eudravigilance Database,” Curr. Oncol., vol. 30, no. 7, pp. 6533–6545, Jul. 2023, doi: 10.3390/curroncol30070479.
S. A. Mehta, A. Ahmed, M. Laverty, R. S. Holzman, F. Valentine, and S. Sivapalasingam, “Sex Differences in the Incidence of Peripheral Neuropathy Among Kenyans Initiating Antiretroviral Therapy,” Clin. Infect. Dis., vol. 53, no. 5, pp. 490–496, Sep. 2011, doi: 10.1093/cid/cir432.
H. Jeong, “Altered Drug Metabolism During Pregnancy: Hormonal Regulation of Drug-Metabolizing Enzymes,” Expert Opin. Drug Metab. Toxicol., vol. 6, no. 6, pp. 689–699, Jun. 2010, doi: 10.1517/17425251003677755.
S. L. Klein and K. L. Flanagan, “Sex Differences in Immune Responses,” Nat. Rev. Immunol., vol. 16, no. 10, pp. 626–638, Oct. 2016, doi: 10.1038/nri.2016.90.
Y. Zhu, X. Song, R. Li, H. Quan, and L. Yan, “Assessment of Nasopharyngeal Cancer in Young Patients Aged ≤ 30 Years,” Front. Oncol., vol. 9, pp. 1–8, Nov. 2019, doi: 10.3389/fonc.2019.01179.
V. Verma, S. M. Surkar, A. C. Moreno, C. Lin, and C. B. Simone, “Practice Patterns and Outcomes of Chemoradiotherapy Versus Radiotherapy Alone For Older Patients with Nasopharyngeal Cancer,” Cancer Med., vol. 7, no. 5, pp. 1604–1611, May 2018, doi: 10.1002/cam4.1290.
Y. Lu et al., “Combined Radiotherapy and Chemotherapy Versus Radiotherapy Alone in Elderly Patients with Nasopharyngeal Carcinoma,” Medicine (Baltimore)., vol. 100, no. 29, pp. 1–8, Jul. 2021, doi: 10.1097/MD.0000000000026629.
J.-D. Xie et al., “Old Age at Diagnosis Increases Risk of Tumor Progression in Nasopharyngeal Cancer,” Oncotarget, vol. 7, no. 40, pp. 66170–66181, Oct. 2016, doi: 10.18632/oncotarget.10818.
P. Blanchard et al., “Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma: An Update of The MAC-NPC Meta-Analysis,” Lancet Oncol., vol. 16, no. 6, pp. 645–655, Jun. 2015, doi: 10.1016/S1470-2045(15)70126-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Fera Dilla Putri Deli, Reeny Purnamasari Juhamran, Sri Irmandha Kusumawardhani, Andi Tenri Sanna, Ahmad Ardhani Pratama, Poentoro Poentoro
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
